Factor V activity in apheresis platelets: Implications for management of FV deficiency.

Background: Allogeneic platelet (PLT) infusion is a strategy to raise Factor V (FV) levels in patients with congenital FV deficiency. However, since FV is labile in vitro, we hypothesized that FV activity could be low in PLT units. Study Design and Methods: FV activity was tested using a prothrombin time‐based platform in the supernatant and platelet lysate (PL) of apheresis PLT units (16 units stored in PLT additive solution with acetate and phosphate [PAS‐C] and 10 units stored in plasma only), on post‐collection days 3‐6. Statistical analysis was performed using Student's t test (P <.05). Results: FV activity was severely diminished in PAS‐C PLTs (N = 16) supernatant (3.70% ± 1.02%) and PL (3.26% ± 1.02%). FV activity in plasma‐only PLTs (N = 10) was lower in both supernatant (44.55% ± 6.46%) and lysate (39.67% ± 6.33%) relative to normal plasma levels, but both were significantly higher (P <.0001) compared to PAS‐C PLTs. In a separate set of experiments, FV activity in PAS‐C PLTs examined serially over storage time (N = 3 for these experiments) showed that FV levels were reduced by day 3 and not significantly different by day 5 of storage (Day 3 supernatant 5.03% ± 1.41%; Day 5 supernatant: 3.10% ± 0.57%; P =.2; Day 3 lysate: 3.89% ± 1.03%; Day 5 lysate: 2.61% ± 0.41%; P =.4). Conclusion: Plasma should be considered over PLTs as first‐line therapy for non‐complex FV deficiency‐associated hemorrhage. If PLTs are considered for transfusion, plasma‐only PLT units should be preferentially utilized, as PAS‐C PLT have near‐absent FV activity. [ABSTRACT FROM AUTHOR]